On behalf of AbbVie, I would like to invite you to an informative discussion on ELAHERE® (mirvetuximab soravtansine-gynx) For FRα-Positive Platinum-Resistant Ovarian Cancer: Considerations for Nurses and Pharmacists. Please see the following details about the event.
Wednesday, June 18, 2025
Arrival time: 5:45 PM Program time: 6:00-7:00 PM
The Waterfront Restaurant and Tavern
328 Front Street SLa Crosse, WI 54601
Should you have questions, please feel free to reach out to me directly. Please RSVP by June 15, 2025 to myself or Heidi Homme, RN, MSN, OCN, at Heidi.homme@abbvie.com or (262)389-6526.
Best,Kami McVeigh, MSN, FNP-C, Oncology Nurse Educator
1 N Waukegan RdBldg. ABV1, 3C 305 03 North Chicago, IL 60064